Employees: 102
Size Verastem (VSTM) is a United States Health Care company (Biotechnology) with a market value of $866M, the 2316th largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.87 on 18 Nov 2026.
Performance Over six months the shares gained 66.3%, against -16.4% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 20 in its peer set.
Growth Revenue grew 649.6% over the last twelve months (peer median +2.5%); the operating margin is -193.7% (peer median -25.0%).
Valuation It trades at 8.2× enterprise value to sales against a peer median of 6.4× (8th most expensive of 19).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $100M | $30.9M | $10.0M | $0 | $0 |
| Revenue growth | — | +209% | — | — | — |
| Gross profit | $86.4M | $25.6M | $9.97M | -$62,000 | -$118,000 |
| EBITDA | -$193M | -$169M | -$115M | -$92.0M | -$75.4M |
| Net income | -$179M | -$209M | -$131M | -$87.4M | -$73.8M |
| Free cash flow | -$160M | -$138M | -$105M | -$86.5M | -$63.7M |
| Capital expenditure | $8.85M | $9.62M | $28,000 | $0 | $0 |
| Total debt | $129M | $87.2M | $42.3M | $41.6M | $27.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VSTM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -26.4% | -7.2% | 4th lowest of 21 |
| 6-month return | +66.3% | -16.4% | highest of 20 |
| Distance from 52-week high | -36.5% | -44.8% | 6th highest of 21 |
| Revenue growth (TTM) | +649.6% | +2.5% | 2nd highest of 18 |
| Operating margin | -193.7% | -25.0% | 5th lowest of 19 |
| EV / Sales | 8.2× | 6.4× | 8th most expensive of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Verastem VSTM | United States | $866M | +66% | +650% | -194% | 8.2× | n/a | n/a |
| Peptidream 4587.T | Japan | $878M | -3% | +14% | -18% | 6.6× | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $841M | -15% | +16% | -18% | 4.1× | n/a | n/a |
| GNI 2160.T | Japan | $903M | -25% | +44% | -21% | 6.2× | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $909M | -15% | 0% | 22% | 4.2× | 9.2% | +2.3% |
| Odyssey Therapeutics ODTX | United States | $912M | +12% | -33% | -5,415% | 204.9× | n/a | n/a |
| Innovita Biological Technology 688253.SS | China | $915M | -28% | -28% | 11% | 14.0× | 39.6% | -16.6% |
| China Animal Husbandry Industry 600195.SS | China | $921M | -16% | +1% | 2% | 1.3× | 6.1% | +4.4% |
| MeiraGTx MGTX | United States | $813M | -13% | +1,366% | 44% | 1.9× | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $780M | -24% | -22% | 20% | 4.4× | 7.8% | +2.4% |
| Monte Rosa Therapeutics GLUE | United States | $775M | -51% | -61% | -214% | 3.3× | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $771M | -57% | +160% | -62% | 3.2× | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $764M | -50% | n/a | -108% | 21.1× | n/a | n/a |
| Inventiva IVA.PA | France | $763M | -36% | -100% | -307,063% | 12,169.8× | n/a | n/a |
| Changchun BCHT Biotechnology 688276.SS | China | $992M | -2% | +2% | -29% | 9.9× | n/a | n/a |
| SpyGlass Pharma SGP | United States | $993M | +36% | n/a | n/a | n/a | n/a | n/a |
| Aura Biosciences AURA | United States | $743M | -4% | n/a | n/a | n/a | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | 6.9× | -13.5% | -10.9% |
| Inhibrx Biosciences INBX | United States | $1.02B | -37% | +43% | -6,287% | 551.0× | n/a | n/a |
| Apnimed APMD | United States | $726M | n/a | +380% | -140% | 10.8× | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $722M | -11% | +21% | 11% | 3.4× | 17.3% | +11.8% |